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Introduction: Protein deimination, defined as the post-translational conversion of protein-bound arginine to
citrulline, is carried out by a family of 5 calcium-dependent enzymes, the peptidylarginine deiminases (PADs)
and has been linked to various cancers. Cellular microvesicle (MV) release, which is involved in cancer
progression, and deimination have not been associated before. We hypothesize that elevated PAD expression,
observed in cancers, causes increased MV release in cancer cells and contributes to cancer progression.
Background: We have previously reported that inhibition of MV release sensitizes cancer cells to
chemotherapeutic drugs. PAD2 and PAD4, the isozymes expressed in patients with malignant tumours, can
be inhibited with the pan-PAD-inhibitor chloramidine (Cl-am). We sought to investigate whether Cl-am can
inhibit MVrelease and whether this pathway could be utilized to further increase the sensitivity of cancer cells to
drug-directed treatment.
Methods: Prostate cancer cells (PC3) were induced to release high levels of MVs upon BzATP stimulation of
P2X7 receptors. Western blotting with the pan-protein deimination antibody F95 was used to detect a range
of deiminated proteins in cells stimulated to microvesiculate. Changes in deiminated proteins during
microvesiculation were revealed by immunoprecipitation and immunoblotting, and mass spectrometry
identified deiminated target proteins with putative roles in microvesiculation.
Conclusion: We report for the first time a novel function of PADs in the biogenesis of MVs in cancer cells. Our
results reveal that during the stimulation of prostate cancer cells (PC3) to microvesiculate, PAD2 and PAD4
expression levels and the deimination of cytoskeletal actin are increased. Pharmacological inhibition of PAD
enzyme activity using Cl-am significantly reduced MV release and abrogated the deimination of cytoskeletal
actin. We demonstrated that combined Cl-am and methotrexate (MTX) treatment of prostate cancer cells
increased the cytotoxic effect of MTX synergistically. Refined PAD inhibitors may form part of a novel
combination therapy in cancer treatment.
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M
icrovesicles (MVs) are defined as intact, sub-
micron, phospholipid-rich vesicles that are
ubiquitously released from the cell membrane
of diverse cell types upon stimulation and/or apoptosis
(1). As cells are constantly challenged in the environment
by various factors ranging from chemical to physical

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stress, a variety of vesicles are released that differ in size
and composition depending on the status and origin of
the cell (2).
Cell activation and subsequent MV release have been
shown to depend on an influx of calcium ions through
pores made by sublytic complement, or released by
the endoplasmic reticulum (ER) and through various cal-
cium channels on activated cells (1,3). The rise in cy-
tosolic calcium leads to the activation of enzymes such as
calpain, gelsolin, scramblase as well as protein kinases.
Simultaneously, enzymes such as translocase and phos-
phatases are inhibited, therefore resulting in cytoskeletal
reorganisation, loss of membrane asymmetry, membrane
blebbing and MV formation and release (4).
Over the last decade, MVs have been implicated to play
roles directly or indirectly in the pathogenesis of various
diseases including cancer. The presence of MVs in cancer
patients had already been noticed since the late 1970s (5)
and various investigators demonstrated elevated levels
of MVs in the blood from cancer patients compared to
healthy individuals (68). Physiologically, MVs have been
identified as mediators of intercellular communication by
transferring growth factors, micro RNAs and enzymes
between cells and therefore influencing processes as diverse
as differentiation, migration and angiogenesis (9,10). This
mechanism has also been shown to aid tumour survival
and spread as the various soluble proteins, pathological
growth factor receptors and micro RNAs are transported
via MVs (9,10).
MV release has also been identified as one of the
mechanisms contributing to cancer drug resistance, as
cancer cells can evade chemotherapeutic agents by in-
creasing active drug efflux through MV shedding (11,12).
In the same vein, recent work from our laboratory has
shown that by inhibiting microvesiculation of cancer cells
their resistance to anticancer drug treatment with metho-
trexate (MTX) is reduced (12).
Protein deimination is a post-translational modifica-
tion caused by a family of Ca2-dependent enzymes, the
peptidylarginine deiminases (PADs) (13). Protein deimi-
nation is the irreversible post-translational conversion of
protein-bound arginine and positively charged methylar-
ginine residues to the neutral amino acid, citrulline. This
leads to structural and functional changes in target
proteins and has critical physiological and pathological
consequences (1416).
In mammals, 5 PAD isozymes (PADs 14 and 6) have
been identified that exhibit tissue-specific expression
patterns, vary in their subcellular localisation and selec-
tively target proteins (15,17,18). In humans, the PAD
genes are localised to a well-organized gene cluster at
1p36.13, which is also identified to be the cluster region
for the tumour suppressor gene RUNX3 (19).
While PAD-mediated protein deimination regulates
numerous physiological functions, PAD dysregulation
and resulting changes in protein deimination are impli-
cated in central nervous system damage (20,21), neuro-
degenerative diseases (22), various human autoimmune
diseases (2325) and cancer (26). Both PAD2 and PAD4
isozymes have been linked with cancer and are reported
to be overexpressed in blood and tissues of patients
suffering from malignant tumours (3,27,28).
PAD2 is the most broadly expressed PAD isozyme in
the body, detected in multiple organs including cells of
the haematopoietic lineage, spleen, secretory glands and
brain (2931). Known PAD2 substrates include myelin
basic protein in the nervous system (32) and vimentin, an
intermediate filament that provides support to cell
organelles in conjunction with the cytoskeleton (33,34).
Importantly, PAD2 has been shown to play a role in gene
regulation in breast cancer cells (28,35).
PAD4 is the most characterised PAD isozyme and is
expressed mainly in haematopoietic progenitor cells and
cells of the immune system (granulocytes, monocytes and
natural killer cells). It is the only isoform to contain a
classic nuclear localisation signal and is commonly
localised in the nucleus of the cell (34,3638) although
recently PAD2 and PAD3 have also been reported in the
nucleus (21,28,39). PAD4 has been shown to translocate
to the nucleus in response to upregulated tumour necrosis
factor alpha (TNFa) (40), as well as to play a role in
innate immunity by the formation of neutrophil extra-
cellular traps during bacterial infection (23,36,41). PAD4
acts as a transcriptional co-regulator for a range of
factors such as p53, p300, p21 and ELK1. This regula-
tory function of PAD4 is thought to be mediated via
deimination of the N-terminal tails of various histone
proteins (4244). PAD4 also acts as a co-mediator of
gene transcription and epigenetic cross talk with histone
deacetylase 2 (HDAC2) to regulate p53 gene activity
during DNA damage playing a role in apoptosis (45).
PAD4 has been co-localised with cytokeratin (CK), an
established tumour marker. Various isoforms of CK (CKs
8, 18, and 19) are deiminated, making them resistant to
caspase-mediated cleavage, in turn, contributing to the
disruption of apoptosis in cancer tumours (46). PAD4 has
also been linked with the regulation of oestrogen receptor
target gene activity, mediated by oestrogen stimulation via
histone tail deimination (47). In addition, the PAD4
isozyme has been shown to act as a cofactor in epidermal
growth factor mediated target gene activity activating the
expression of the proto-oncogene c-fos (44), interacting
with p53 and influencing the expression of its target genes
(42,43,48,49).
As both microvesiculation and PAD enzyme activation
are calcium-dependent events that have been shown to be
elevated in certain human diseases including autoimmune
diseases and cancer (22,23,26,35,50,51), we hypothe-
sized that PAD enzyme activation and microvesicula-
tion might play synergistic roles in cancer progression.
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Here, we demonstrate this association in the prostate
cancer cell line, PC3.
Materials and methods
Cell culture
The highly metastatic prostate cancer cell line PC3
(SigmaAldrich, Gillingham, U.K.) and a control immor-
talised normal prostate cell line (PNT2; ECACC) were
cultured in MV-free complete growth medium (CGM)
consisting of EMV (exosome and MV)-free RPMI 1640
supplemented with 10% EMV-free foetal bovine serum
(FBS; Hyclone, Thermo Scientific, Paisley, UK) in the
absence of antibiotics. The CGM medium supplemented
with 10% FBS was then centrifuged at 100,000g for 2 h to
remove exosomes and MVs before using it in cell culture.
EMV-free RPMI, phosphate-buffered saline (PBS), nor-
mal human serum (NHS) and FBS were prepared by
centrifugation (100,000g/2 h) and filtering (0.1 mm pore
size filter).
Purification of MVs
MVs were purified according to previously established
protocols (52). In brief, the supernatant was collected from
the cell cultures following experiments and centrifuged
once at 200g for 5 min to remove the cells. The supernatant
was then centrifuged at 4,000g for 1 h to remove cell debris
and further at 15,000g for 2 h to pellet MVs, which were
then washed once by resuspending in sterile, EMV-free
PBS and centrifuged again at 15,000g for 2 h. The MV
pellet was resuspended in sterile, EMV-free, MV-free PBS
and quantified [by nanoparticle tracking analysis (NTA),
as described below], or analysed for phosphatidylserine
exposure (52) or quantified using the Guava EasyCyte
microcapillary flow cytometer (10,000 events, 0.24 ml/s
flow rate).
PAD isotype expression in cancer and
non-cancerous cells
To determine the PAD isotype expressed in cancer and
control cells, PC3 and PNT2 cells were labelled with PAD2
and PAD4 antibodies and analysed by flow cytometry,
fluorescence microscopy and Western blotting.
Flow cytometry
In brief, 5105 viable cells were placed in 1.5 ml
Eppendorf tubes in triplicate and fixed with 4% parafor-
maldehyde (PFA) for 10 min at room temperature (RT).
The cells were then washed 3 times with cold EMV-free
PBS at 400g for 5 min and resuspended in permeabilisation
buffer (PB: 0.5% Triton-X 100 in PBS) for 5 min at RT.
Permeabilised cells were washed 3 times and incubated
with primary antibody (PAD2 or PAD4, 1:500 in 3% BSA/
PBS) at 48C for 1 h on a shaking platform. The cells were
washed 3 times and incubated with FITC-conjugated anti-
rabbit IgG (SigmaAldrich) in 3% BSA/PBS at 48C for 1 h,
washed 3 times with cold 1% BSA/PBS again and resus-
pended in 200 ml of PBS containing 3% BSA, 1% NaN3 and
analysed by flow cytometry using the Guava EasyCyte
microcapillary flow cytometer at a flow rate of 0.56 ml/s.
NTA protocol
The particles present in samples were measured by NTA,
using the NTA (NS500; Nanosight, Amesbury, UK),
equipped with an sCMOS camera and a 405 nm diode
laser. Data acquisition and processing were performed
using the NTA software version NTA 3.0 0068. Back-
ground extraction was applied together with automatic
settings for the minimum expected particle size, minimum
track length and blur and the ambient temperature was
set at 238C. Silica beads (100 nm diameter; Microspheres-
Nanospheres, Cold Spring, NY, USA) were used to
configure and calibrate the instrument. Samples were
diluted 10- to 50-fold in particle-free PBS to maintain the
number of particles in the field of view between
approximately 20 and 40 particles. For each sample, 4
videos of 30 s duration were recorded generating replicate
histograms that were averaged. Only measurements with
at least 1,000 completed tracks were analysed (53).
Fluorescence microscopy
PC3 and PNT2 cells (5105 cells/well) were seeded on
a cover slip in a 24-well plate in triplicate, incubated for
24 h, washed gently with prewarmed PBS, fixed with 4%
PFA for 10 min at RT, washed 3 times with cold PBS and
resuspended in PB for 5 min at RT. The buffer was then
removed and the cells were washed 3 times as before.
After incubation with PAD2 or PAD4 primary anti-
bodies (1:500 dilution in 3% BSA/PBS) for 1 h at 48C on a
shaking platform, the cells were washed 3 times with cold
PBS and further incubated with AlexaFluor 488 conju-
gated anti-rabbit IgG secondary antibody (Invitrogen;
5 mg/ml in 3% BSA/PBS) at 48C for 1 h on a shaking
platform in the dark. The cells were then washed 3 times
with cold 1% BSA/PBS and the cover slips mounted on
to slides with DAPI-VECTASHIELD medium (Vector
Laboratories, Inc., Burlingame, CA, USA). Images were
acquired using a fluorescence microscope (1X81 motorized
inverted fluorescence microscope, Olympus Corporation,
Hamburg, Germany). The mean green fluorescence inten-
sity of the fluorescence images was analysed as per the
manufacturer’s instructions using the CellﬄM imaging
software (Olympus Corporation) provided with the Olym-
pus 1X81 fluorescence microscope (Olympus Corporation).
SDSPAGE
PC3 and PNT2 cells were lysed, diluted in 4 SDS sample
buffer and incubated at 958C for 4 min. Protein electro-
phoresis was performed as previously described (54) using
the Mini PROTEAN III Electrophoresis System (Bio-Rad,
Hemel Hempstead, U.K.) and freshly prepared 8% poly-
acrylamide separating gels. Electrophoretic separation was
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performed at 100 V (constant voltage) and gels were either
stained with Coomassie Brilliant Blue (BDH Ltd, Poole,
England) or transferred onto nitrocellulose membrane
for Western blotting analysis.
Western blotting
SDSPAGE gels were transferred to a Hybond C
nitrocellulose membrane for further analysis using a
semi-dry transfer device (Bio-Rad Sartoblot System).
Blotting paper, nitrocellulose membrane and the sand-
wich-blotting cassette were equilibrated in Sartoblot
buffer. Electroblotting was carried out at 150 mA for 1 h.
The membranes were incubated in blocking buffer (6%
non-fat milk/PBS-T) for 1 h at RT or at 48C, overnight, on
a shaker. Following blocking, the membranes were rinsed
with PBS-T and incubated with the primary antibody for
1 h at RT on a shaker (PAD2, PAD4 1:500, Abcam,
Cambridge, U.K., in 3% non-fat milk/PBS-T). Anti-
b-actin (1:1,000, Santa Cruz, Biotechnology Inc.,
Heidelberg, Germany) was used as a loading control.
Three 10 min washing steps with PBS-T were performed
and the membranes were incubated with secondary HRP-
labelled goat-anti-mouse-IgG antibodies (1:1,000; Sigma
Aldrich) for 1 h at RT. After washing 6 times in PBS-T,
visualization was performed using the enhanced chemilu-
minescence reagent system (ECL, Amersham Pharmacia,
Little Chalfont, U.K.). Chemiluminescence was detected
using the UVP ChemiDoc-It system (UVP Systems,
Cambridge, UK). Where necessary, band intensities on
the Western blot were analysed using Image J software
according to the manufacturer’s instructions.
Nuclear protein preparation
TSSM buffer (20 mM Tris, pH 8; 100 mM NaCl; 300 mM
sucrose; 2 mM MgCl2) with protease inhibitor cocktail was
added to cells on ice for 10 min followed by centrifugation
at 720g for 10 min/48C. The pellet was resuspended in TSS
buffer (20 mM Tris, pH 8; 100 mM NaCl; 2 mM EDTA, pH
8; which was rendered 300 mM NaCl) and then homo-
genised in a Dounce homogeniser (20 strokes on ice), left
on ice for 20 min and then centrifuged at 24,000g for 20 min/
48C. The supernatant was then quantified for protein using
the BCA assay kit (Life Technologies Ltd., Paisley, U.K.).
The effect of PAD inhibition on MV release
To determine the effect of PAD enzyme activity on cellular
MV release, cell cultures were incubated with the irrever-
sible pan-PAD-inhibitor chloramidine (Cl-am) (20).
The cell preparations (quantified and tested for viability)
were washed once with prewarmed EMV-free PBS
(Supplementary Fig. 1), resuspended in prewarmed serum-
and EMV-free RPMI 1640 (100,000g/2 h and filtered
through 0.1 mm pore size membrane) supplemented with
2 mM CaCl2 at 510
5 cells and treated with BzATP
(2?(3?)-O-(4-benzoylbenzoyl)adenosine-5?-trisphosphate
triethylammonium salt (300 mM)) to induce MV release
(378C for 30 min), serial concentrations of Cl-am (ranging
from 5 to 50 mM) being included where necessary to inhi-
bit microvesiculation. In some experiments, cells were
incubated with 10% EMV-free NHS [from Human male
AB plasma, SigmaAldrich; as a source of sublytic com-
plement to stimulate MVs (51)], rendered EMV-free by
centrifugation at 100,000g for 2 h and filtering through a
0.1-mm pore size filter membrane, and further incubated at
378C in a 12-well plate for 30 min with shaking. The plate was
placed on ice for 1 min and the supernatant from each well
was transferred to sterile 1.5 ml Eppendorf tubes on ice and
centrifuged at 200 g for 5 min to remove the cell debris. The
supernatants were treated as described earlier for isolation
of MVs. The resulting MV pellet was suspended in 200 ml of
sterile EMV-free PBS and analysed using the Nanosight
(NS500; Nanosight, Amesbury, UK) or by flow cytometry
(Millipore, Watford, U.K., microcapillary flow cytometer).
Immunoprecipitation (IP) of deiminated target
proteins
To analyse deiminated proteins from experiments in which
cells had been stimulated to microvesiculate, 500 mg of cell
lysates (in RIPA buffer; 150 mM NaCl, 1% IGEPAL CA-
630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris,
pH 8  SigmaAldrich) from PC3 and control cells treated
with or without Cl-am were immunoprecipitated with the
pan-citrulline F95 antibody (4 mg) that specifically recog-
nizes protein bound citrullines (55), using the Catch and
Release v2.0 IP kit (Millipore), according to the manu-
facturer’s instructions. Bound proteins were eluted using
denaturing Elution Buffer containing 5%b-mercaptoethanol
and the eluate stored at 208C for further analysis.
Mass spectrometry analysis of deiminated proteins
from PC3 cells stimulated for microvesiculation
To identify proteins that were deiminated during MV
stimulation of PC3 cells, 2,000 mg of cell lysates from
healthy PC3 cells only, or PC3 cells pretreated with or
without 50 mM Cl-am and then stimulated with 300 mM
BzATP, were immunoprecipitated with F95 antibody and
eluted with 70 ml of non-denaturing buffer 4 times
successively for maximum recovery of protein. The eluate
was then subjected to mass spectrometry analysis.
Mass spectrometry analysis: in-solution trypsin
digestion and MSE label-free quantitation
Protein samples in duplicate were denatured by the addition
of 20 ml of 100 mM Tris-HCl buffer (pH 7.2) supplemented
with 5 M dithioerythreitol and 6 M urea at RT for 60 min
on a shaking platform. Free thiol groups in the samples
were then carboamidomethylated by the addition of 6 ml
of 100 mM Tris-HCl (pH 7.8) supplemented with 5 M
iodoacetamide for 45 min. Next, the samples were incubated
with 180 ml of 1 mg sequence grade trypsin dissolved in
ddH2O for 1216 h at 378C. The samples were centrifuged
and the supernatant was collected and analysed by mass
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spectrometry. Prior to analysis, each digest was spiked
with 1 pmol of an enolase tryptic digestion (Saccharomyces
cerevisiae), which acted as an internal standard for the
quantitation of each protein.
The processed samples were then identified and quanti-
fied by direct analysis using a nanoAcquity UPLC (ultra
performance liquid chromatography) and a QTOF (quad-
rupole time of flight) Premier mass spectrometer (Waters
Corporation, Manchester, UK). Briefly, the samples
were trapped and desalted using a Symmetry C18 5 mm,
5 mm300 mm precolumn in 0.1% formic acid for a total
time of 4 min at a rate of 4 ml/min and then eluted. The
eluate was then separated using a 15 cm75 mm C18
reverse-phase analytical column using a gradient of 340%
acetonitrile containing 0.1% formic acid over a period of
120 min at a flow rate of 250 nl/min. The column was
washed and regenerated at 300 nl/min for 10 min using 99%
acetonitrile containing 0.1% formic acid. After the removal
of all non-peptide and non-polar materials, the column
was re-equilibrated under the initial starting conditions for
20 min. All columns were maintained at 358C (56). After
purification, the samples were analysed in positive ion mode
with the QTOF operated in v-mode with a typical resolving
power of 10,000 fwhm after the calibration of the TOF
analyser. Accurate mass using LC-MS was collected in a
data-independent and alternating, low and collision energy
mode. The data were then processed using the ProteinLynx
GlobalServer version 2.4 (Waters Corporation) (56).
Effect of PAD inhibition on the cytotoxic effect of
methotrexate on cancer cells
To test whether Cl-am would enhance the cytotoxic
effect of MTX, adherent PC3 cells were washed and seeded
at 5104 cells/well in 24-well plates 24 h before the ex-
periment to allow the cells to attach and settle. On the day of
the experiment, the cells were washed once and resuspended
in EMV-free CGM with various concentrations of either
MTX, or chloramidine, or MTX in combination with
100 mM chloramidine (chloramidine having been preincu-
bated for 30 min prior to adding MTX) in triplicate and
incubated for a further 48 h at 378C (5% CO2, humidified
conditions). Cells without any treatments served as controls.
After incubation, the supernatant was collected. The
cells were trypsinised and centrifuged together with
the supernatant at 500 g for 5 min. The wells were then
washed once with prewarmed PBS, which was transferred
to the individual tubes containing the cells. The cells were
centrifuged once more at 500g for 5 min and resuspended
in prewarmed RPMI 1640 and analysed for apoptosis by
flow cytometry using the Guava ViaCount assay (Guava
Millipore) as per the manufacturer’s protocol.
Statistical tests
Statistical analysis was performed by using the Student’s
t-test, one-way analysis of variance (ANOVA) with
Dunnett’s multiple comparison test or two-way ANOVA
with Bonferroni post hoc test where appropriate, using
GraphPad Prism software, version 5.0 (GraphPad
Software, San Diego, CA, USA). Differences giving a
P-valueB0.05 were considered statistically significant.
Results
PAD2 and PAD4 are expressed in both benign
prostate PNT2 cells and PC3 cancer cells
To investigate the role of PAD activity in normal versus
cancer cells, we began by evaluating the expression of PAD
isozymes and found that by Western blotting that PC3 and
PNT2 cells express both PAD2 and PAD4 isozymes, PAD2
and PAD4 being more highly expressed in PC3 than PNT2
cells (Fig. 1a and b). Fluorescent microscopy further
suggested an intracellular, cytoplasmic and perinuclear
location (Supplementary Fig. 2a and b).
PAD2 and PAD4 expression by flow showed higher
detected PAD4 than PAD2 in both cell lines (Fig. 1c),
83% positive cells for PAD4 compared to 38% for PAD2
in PC3 cells (Fig. 1d) and 70% for PAD4 and 30% for
PAD2 in PNT2 cells (Fig. 1e).
Cl-am inhibits microvesiculation in PC3 and PNT2
cells and reduces nuclear PAD translocation during
MV release
The effect of pharmacological inhibition of PAD on
microvesiculation was monitored as the release of PS-
rich vesicles showing a typical Forward/Side Scatter dot
plot, a distinct population averaging at 200 nm in diameter
by electron microscopy or just below 300 nm by NTA
(Supplementary Fig. 3) and with weak expression of
exosome markers TSG101 and Alix. PC3 prostate cancer
cells were pretreated with serial concentrations of Cl-am
and microvesiculation induced with 300 mM BzATP. MVs
were then isolated and enumerated by NTA and flow
cytometry.
Whilst the same trends in MV numbers were noted,
compared to NTA (Fig. 2) flow underestimated levels by
103-fold (Supplementary Fig. 4). Incubating PC3 and
PNT2 cells with BzATP significantly increased the number
of released MVs, whilst preincubating the cells with the
pan-PAD inhibitor, Cl-am (5100 mM), caused a signifi-
cant reduction of microvesiculation (with no concomitant
reduction in cell viability, Supplementary Fig. 5), which in
the case of the NTA measurements was shown to be dose
dependent (Fig. 2). This asserts a functional role of PAD
enzymes in the microvesiculation of both normal and
cancerous prostate cells.
To further identify the localisation of PAD2 and PAD4
enzymes during BzATP stimulation and Cl-am inhibition,
PC3 cells were pretreated with 10 mM Cl-am (30 min at
378C), stimulated with BzATP and labelled with PAD2 or
PAD4 antibody followed by isotype-matched AlexaFluor
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Fig. 1. Immunoblotting and flow cytometry reveal higher detected PAD4 than PAD2 in PC3 and PNT2 cells and higher PAD2/4
expression in PC3 than PNT2 cells. (a and b) Western blot analysis and associated densitometry analysis (using Image J software)
representing band intensity of healthy PC3 and PNT2 controls indicate higher detected PAD4 than PAD2 and of PAD2 and PAD4 in
prostate cancer cells (PC3) compared to benign prostate cells (PNT2). Loading control: b-actin and Coomassie-stained SDSPAGE.
PC3 (c and d) and control PNT2 (c and e) cells were fixed, permeabilised and labelled with anti-PAD2 and anti-PAD4 antibody followed
by FITC-IgG secondary antibody and analysed for PAD expression via flow cytometry. (c) Median fluorescence intensity (MFI) is a
indicative of expression levels of PAD/cell. Significant differences were seen between PAD2 and PAD4 expression in both cell lines.
Histograms in (d) represent% positive PC3/PNT2 cells for PAD2 and PAD4. Data represent the mean9SEM of 2 independent
experiments performed in triplicate. *PB0.05, ***PB0.001.
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488 antibodies and mounted onto slides for fluorescent
microscopy analysis.
Compared to cells stimulated with BzATP to release
MVs (Fig. 3a, d, g and b, j, m), there was a reduced
expression of PAD2 and PAD4 in cells preincubated with
Cl-am (Fig. 3a, e, h and b, k, n) (and in control, untreated
cells, Fig. 3a, c, f and b, i, l). When stimulated to micro-
vesiculate with BzATP, Western blotting showed an in-
creased nuclear localisation of PAD2 and PAD4 (Fig. 4a
and b, respectively) and fluorescence microscopy revealed
a nuclear translocation, as reflected by the increase in
fluorescence intensity from the cytoplasm in unstimulated
cells (Fig. 4c, f, i, l, white arrows) to the nucleus (Fig. 4d, g,
j, m, white arrows) although for PAD2 the fluorescence
was relatively high around the nucleus, suggesting only a
partial transfer. This increase in fluorescence intensity was
reduced, however, upon preincubating cells with Cl-am
prior to BzATP stimulation (Fig. 4e, h, k, n, white arrows).
The cytoskeletal protein b-actin is deiminated by
PADs during MV release
Having shown that PAD inhibition using Cl-am signifi-
cantly reduced microvesiculation in both cancer and
control cells, we hypothesized that actin filaments, which
form part of the cytoskeleton and undergo considerable
rearrangement allowing the shedding of MVs (1), might
be affected by changes in deimination, leading to reduced
MV release.
PC3 cells (1107) pretreated with 10 mM Cl-am were
stimulated to microvesiculate as before. PC3 cells without
any treatment served as controls. After incubation, the
cells were washed and lysed with RIPA buffer and 500 mg
of protein lysates from each treatment group immunopre-
cipitated using the pan-deimination F95 antibody and
immunoblotted with anti-b-actin. Untreated PC3 cells had
a very low expression of deiminated b-actin (Fig. 5a, L2
and Fig. 5b), whereas cells stimulated to microvesiculate
had approximately 4 times greater levels (Fig. 5a, L3 and
Fig. 5b). Cells that were preincubated with Cl-am and then
stimulated to microvesiculate displayed a band inten-
sity of b-actin twice as high as the control, but almost
twice as low as BzATP-stimulated cells untreated with the
PAD inhibitor (Fig. 5a, L1).
Mass spectrometry analysis of deiminated protein
candidates from PC3 cells stimulated for
microvesiculation
Further to the likely involvement of deiminated b-actin in
MV release, we repeatedly observed increased levels of
deimination, comparing Western blots for deiminated
proteins in stimulated versus resting cells (not shown).
Whether such increases were of particular proteins or a
global increase, we could not be sure, but with the aim to
understand the involvement of PAD-mediated protein
deimination in microvesiculation, we set out to identify
further target proteins. Cell lysates from the 3 treatment
groups: (a) untreated PC3 cells, (b) PC3 cells stimulated
with BzATP and (c) PC3 cells treated with Cl-am prior to
BzATP stimulation were immunoprecipitated with F95
antibody for the isolation of deiminated proteins. The
eluates were then subjected to mass spectrometry analysis
to identify differences in deiminated proteins that were
present in each of the 3 samples.
Using ProteinLynx Global SERVER version 2.4 to
process the data obtained from the analysis, deiminated
proteins were identified through the human proteome
Fig. 2. PAD inhibition reduces microvesiculation in PC3 prostate cancer and PNT2 control cells. PC3 and PNT2 cells pretreated with or
without various concentrations of PAD-inhibitor chloramidine (Cl-am) were stimulated with BzATP and incubated at 378C for 30 min.
MVs were then isolated and counted by NTA (a and b). Significant reductions in microvesicle release were detected upon treatment with
Cl-am. The data are represented as the mean9SEM of 3 experiments performed in triplicates. **PB0.005 and ***PB0.001 were
considered statistically significant (one-way ANOVA).
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Fig. 3. Increased expression of PAD2 and PAD4 upon microvesiculation is inhibited by chloramidine. Mean green fluorescence
intensity [for PAD2 (a) and PAD4 (b)], as determined using CellﬄM imaging software on fluorescent microscopy images [panels (ce)
and (ik)], respectively, indicates increased expression of PAD2 and 4 during BzATP stimulation of MV release. These values were
obtained from PC3 cells preseeded on coverslips and pretreated with 10 mM Cl-am (e, h, k, n) or without Cl-am (d, g, j, m) for 30 min
at 378C. The cells were then washed and incubated at 378C for 30 min in the presence (d, e, g, h and j, k, m, n) or absence (c, f, i, l)
of 300 mM BzATP. (d, g, j, m) PAD2 and PAD4 (green) expression in PC3 cells are increased in response to stimulation of MV release
(BzATP treatment) and reduced upon Cl-am treatment (e, h, k, n). (fh) and (ln) represent merged images of (ce) and (ik)
respectively with nuclear (DAPI) staining. Scale bars  100 mm, white bar, 20 mm.
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Fig. 4. Nuclear PAD2 and PAD4 translocation during microvesiculation of PC3 cancer cells is reduced upon PAD inhibition. (a and b)
Nuclear preparations indicate increased expression of PAD2 and PAD4, by Western blot, during BzATP-induced MV release. Cl-am
treatment appears to reduce nuclear translocation of PAD2 and PAD4 (e, h, k, n). Panels in Fig. 4cn represent magnified images of
white squares in Fig. 3 (nuclear PAD2 and PAD4 expression indicated by white arrows). Scale bars: 100 mm.
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UniProt database. As only duplicate samples were avail-
able, this was very much an exploratory experiment to
indicate likely deiminated candidate proteins for future
study. Altogether, 6 proteins were identified to be deimi-
nated in PC3 cells (untreated and BzATP stimulated)
excluding Yeast Enolase 1 (P00924), which is a protein that
was not part of the sample, but was added manually as part
of the analysis process. Of the 5 proteins found to be
deiminated in PC3 cells without any stimulation or PAD
inhibition (Table I), 4 had a confidence score of 2 (95%
confidence  low probability of false positive; see ‘‘OK’’
column in Table I) and one protein had a confidence score
of 1 (50% confidence  high probability of false positive).
Actin alpha skeletal muscle was identified to be
deiminated in untreated and BzATP-stimulated PC3 cells
although with a reduced relative abundance upon Cl-am
treatment. It is a highly conserved protein and plays a
role in cell motility and microvesiculation. Glyceraldehyde-
3-phosphate dehydrogenase deiminated in untreated PC3
cells is a multifunctional enzyme involved in glycolysis,
nuclear functions such as transcription and DNA repli-
cation, as well as apoptosis (57) and has also been impli-
cated to play a role in the organization and assembly of
the cytoskeleton (58).
Deiminated nucleoside diphosphate kinase B was
identified with high confidence only in untreated PC3
cells. It is involved in the synthesis of nucleoside triphos-
phates apart from ATP and has been identified as a
candidate tumour metastasis suppressor, has histidine
protein kinase activity and is a transcriptional activa-
tor of the regulatory myc gene that has been associated
with cancer formation (59,60). Putative elongation factor
1 alpha like 3 as a deiminated protein was identified in
untreated PC3 cells only. This protein has been reported
to promote GTP-dependent binding of aminoacyl-tRNA
to the A-site of ribosomes during protein synthesis (61).
Deiminated splicing regulatory glutamine lysinerich
protein 1 was identified with high confidence level only
in PC3 cells stimulated with BzATP. Its function is to
regulate alternative splicing by modulating the activity of
other splice factors during RNA splicing (61).
The PAD and microvesiculation inhibitor Cl-am
sensitizes PC3 cells to methotrexate-mediated
cytotoxicity
As Cl-am inhibits microvesiculation in PC3 cells, we
sought to investigate whether treating cells with Cl-am in
combination with MTX would affect cell survival. PC3
cells pretreated with Cl-am were given MTX in the range
0.001100 mM (in the presence of CaCl2). After 24 h,
the cells displayed a healthy morphology but over a 48-h
period, increases in apoptosis were observed. PC3 cells
treated with 1 mM MTX alone showed a significant in-
crease in apoptosis to 22% over controls but when pre-
treated with 1 mM Cl-am, this increased to 47% (Fig. 6a).
Cl-am (1 mM) alone only increased apoptosis to 6%
compared to untreated control (4% apoptosis). Repre-
sentative dot plots at 48 h using the highest concen-
trations of Cl-am and MTX (100 mM) are presented in
Fig. 6b. Cl-am combined with MTX treatment thus had a
synergistic effect on PC3 cancer cell viability over a 48-h
period.
Discussion
The role of MVs in helping maintain the delicate balance
between health and disease has become a burgeoning
field within biomedical research (62). Apart from playing
roles in various physiological functions including throm-
bosis, inflammation, angiogenesis, cellular cross talk and
vasoconstriction (6366), MVs have been linked with a
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Fig. 5. MV stimulation of PC3 cells leads to increased b-actin
deimination that is reduced upon PAD inhibition. PC3 cells
were stimulated with BzATP to microvesiculate and total
deiminated proteins immunoprecipitated using the F95 pan-
deimination protein antibody. (a) Increased deiminated b-actin
was observed in PC3 cells stimulated to microvesiculate with
BzATP (Lane 3) compared to untreated, control PC3 cells (Lane
2). Upon treatment with 10 mM of the pan-PAD-inhibitor Cl-am
prior to MV stimulation, a significant decrease was observed in
the levels of deiminated b-actin (Lane 1). Equal amounts of
protein extract immunoprecipitated with F95 were loaded as
shown by Coomassie blue staining. (b) A bar chart representing
deiminated b-actin band intensity as measured by protein
densitometry and normalised intensity (calculated in Image J)
from each of the treatments immunoblotted in (a).
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wide range of clinical conditions such as diabetes, and
cancer as well as cardiovascular, inflammatory and auto-
immune disease (50,51,6769). Similarly, the PAD group
of enzymes, which catalyses post-translational deimina-
tion of various target proteins, is receiving increasing
interest in the medical and pharmacological fields due to
implications in various autoimmune and neurodegenera-
tive diseases, neuronal damage (20,21) as well as in the
biology of cancer (26).
However, to date no studies have aimed at elucidating
any synergistic link between these 2 calcium-dependent
mechanisms in cancer biology. Also, MV release being
implicated in cancer progression and a significant ex-
pression of PAD4 has been reported in many tumour
tissues including various forms of adenocarcinomas,
breast carcinoma and malignant tumours as well as in
the blood of cancer patients (3,46). In addition, various
functions of PAD4 in cancer survival and progression
have also been postulated. For example, CK, part of the
cytoskeleton, has been identified as a deiminated target
protein of PAD4. CK also plays a role in caspase-
mediated apoptosis and is a potential tumour marker.
Table I. Protein identities of deiminated protein candidates from PC3 cell lysates stimulated for microvesiculation
OK Accession Entry Description Mol. wt (Da) pI (pH)
(A) PC3 cells (untreated)
2 ENO1_YEAST P00924 Enolase1 OS Saccharomyces cerevisiae strain
ATCC 204508 S288c GN ENO1 PE 1 SV 3
46,787 6.1538
2 NDKB_HUMAN P22392 Nucleoside diphosphate kinase B OS Homo
sapiens GN NME2 PE 1 SV 1
17,286 8.7568
2 EF1A3_HUMAN Q5VTE0 Putative elongation factor 1 alpha like 3 OS Homo
sapiens GN EEF1A1P5 PE 5 SV 1
50,153 9.4131
2 G3P_HUMAN P04406 Glyceraldehyde-3 phosphate dehydrogenase OS
Homo sapiens GN GAPDH PE 1 SV 3
36,030 8.6968
1 C170L_HUMAN Q96L14 Cep170-like protein OS Homo sapiens GN
CEP170P1 PE 5 SV 2
32,628 5.3335
2 ACTS_HUMAN P68133 Actin alpha skeletal muscle OS Homo sapiens GN
ACTA1 PE 1 SV 1
42,023 5.0713
(B) PC3 cellsBzATP
2 ENO1_YEAST P00924 Enolase1 OS Saccharomyces cerevisiae strain
ATCC 204508 S288c GN ENO1 PE 1 SV 3
46,787 6.1538
2 SREK1_HUMAN Q8WXA9 Splicing regulatory glutamine lysine-rich protein
1 OS Homo sapiens GN SREK1 PE 1 SV 1
59,345 10.8721
2 ACTS_HUMAN P68133 Actin alpha skeletal muscle OS Homo sapiens GN
ACTA1 PE 1 SV 1
42,023 5.0713
1 G3P_HUMAN P04406 Glyceraldehyde 3 phosphate dehydrogenase
OS Homo sapiens GN GAPDH PE 1 SV 3
36,030 8.6968
1 TBA1B_HUMAN P68363 Tubulin alpha 1B chain OS Homo sapiens GN
TUBA1B PE 1 SV 1
50,119 4.7622
1 TNNT3_HUMAN P45378 Troponin T fast skeletal muscle OS Homo sapiens
GN TNNT3 PE 1 SV 3
31,805 5.5869
(C) PC3 cellschloramidineBzATP
2 ENO1_YEAST P00924 Enolase1 OS Saccharomyces cerevisiae strain
ATCC 204508 S288c GN ENO1 PE 1 SV 3
46,787 6.1538
1 ACTS_HUMAN P68133 Actin alpha skeletal muscle OS Homo sapiens GN
ACTA1 PE 1 SV 1
42,023 5.0713
1 NDKA_HUMAN P15531 Nucleoside diphosphate kinase A OS Homo
sapiens GN NME1 PE 1 SV 1
17,137 5.7671
1 TNNT3_HUMAN P45378 Troponin T fast skeletal muscle OS Homo sapiens
GN TNNT3 PE 1 SV 3
31,805 5.5869
Cell lysates in duplicate from untreated PC3 cells (A), PC3 cells stimulated with BzATP for MV release (B) and PC3 cells treated with
PAD-inhibitor Cl-am prior to BzATP stimulation (C) were immunoprecipitated with the pan-protein deimination antibody F95. The eluates
were analysed by MSE label-free quantitation UPLC-Q/TOF mass spectrometry. The ‘‘OK’’ column simplifies information about data
quality and confidence score (295%, 150%).
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When deiminated, CK is prevented from being cleaved by
caspase, resulting in the inhibition of apoptosis of
tumour cells (46); this is intriguing in the context of
MV release which is a feature of cells in early apopto-
sis. Another deiminated protein target of PAD4 is anti-
thrombin, which loses its ability to inhibit thrombin and
has various pro-cancer functions such as cell prolifera-
tion, angiogenesis and fibrin formation (46).
PAD4 function has also been associated with cancer
epigenetics (70) through deimination of histone proteins
that play a role in the regulation of various genes,
including the tumour suppressor gene p53 (45). Pre-
viously, elevated PAD4 levels have been detected in
prostate adenocarcinoma (46). We now show, similarly,
that PAD isotypes 4 (and 2) are present at significantly
elevated levels in metastatic prostate cancer cells (PC3)
compared to the benign (PNT2) prostate cell line.
We report for the first time, that, upon stimulating cells
to microvesiculate, nuclear translocation of PAD4 and a
partial nuclear translocation of PAD2 was observed in
PC3 cancer cells. Upon pharmacological inhibition of
PAD activation prior to stimulating MV release, this
nuclear PAD translocation was prevented. Furthermore,
a dose-dependent inhibitory effect of PAD-inhibitor
Cl-am on MV release was revealed in both tumorigenic
and non-tumorigenic cell lines. Our data indicate that
ATP stimulation appears to be associated with elevated
MV release and translocation of PAD, especially PAD4.
However, at this stage we cannot say whether this
translocation per se is directly involved in MV release or
conversely that MV release causes translocation. Specific
PAD isozymes may yet be found to play a crucial role in the
shedding of MVs and this is on-going work. A similar
effect of PAD-inhibitor Cl-am was also observed with the
normal prostate (PNT2) epithelial cells, indicating that
PAD activity could have a significant role in the release of
MVs in both cancerous and non-cancerous cells. As Cl-am
acts as a pan-PAD inhibitor, it cannot be stipulated at this
stage which particular PAD isozyme(s) (PAD2 or PAD4 ) is
the main one in this process (or indeed whether they are
equally important).
The mechanism of MV release may be regulated by
influx of Ca2 released by the ER or Ca2 entering the
cell through pores made by sublytic complement (62) or
through various calcium channels (71,72) on activated
cells that bring about calpain-mediated cleavage of
various cytoskeletal actin filaments leading to reorgani-
sation of the cytoskeleton and facilitating MV release
(73). Actins have been shown to play an important role
during microvesiculation, and both b-actin and F-actin
stress fibres are involved in the redistribution of the actin-
cytoskeleton during MV formation through the activa-
tion of Rho/Rho-associated kinase (ROCK) pathways
during apoptosis and thrombin stimulation (74). As both
b- and g-actins have been identified as deiminated target
proteins in sera and synovial fluid from patients with
rheumatoid arthritis (75), we sought to establish whether
there is a link between deiminated b-actin and micro-
vesiculation. Our data show that deiminated b-actin is
increased upon stimulating PC3 and PNT2 cells with
BzATP, and markedly decreased when pretreating the
cells with PAD inhibitor prior to stimulation with BzATP.
Although some deiminated proteins were identified in
PC3 cells pretreated with the PAD-inhibitor, none had a
confidence score of 95% (Table I, C).
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Fig. 6. The pharmacological PAD-inhibitor Cl-am synergisti-
cally increases the cytotoxic effects of the cancer drug metho-
trexate in PC3 prostate cancer cells. (a) PC3 cells were treated
with Cl-am alone (0.001100 mM) or with Cl-am fixed at 100 mM
in combination with MTX (0.001100 mM); MTX (0.001
100 mM) without any Cl-am was also used. Over a 48-h period,
cells treated with 1 mM Cl-am alone had a slightly reduced
viability showing average apoptosis levels of 6% compared to the
highly viable, untreated cells (4% apoptosis). PC3 cells treated
with 1 mM MTX alone showed a significant reduction in
viability (apoptosis at 22%) compared to control cells. Com-
bined treatment of 1 mM Cl-am with 1 mM MTX increased
apoptosis to around 47%, indicating a synergistic effect of Cl-am
and MTX treatment on PC3 cancer cell viability over a 48-h
period. (b) Dot plot presentation of apoptosis (Annexin V) of
PC3 cells after the 48-h incubation period with maximum
concentrations of MTX, Cl-am (100 mM) or Cl-am/MTX from
(a). *PB0.05, ***PB0.001.
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Our work implies the involvement of PAD enzymes
in MV release through deimination of target proteins
involved in cytoskeletal rearrangement, which is an
essential part of MV biogenesis. Further support comes
from identification of actin alpha 1 as a deiminated
protein target. Its confidence level was reduced to 50% in
PC3 cells when pretreated with Cl-am prior to stimula-
tion, suggesting that deimination of actin alpha-1, in
addition to b-actin, may play an important role in the
shedding of MVs. PAD upregulation and the resulting
increase in deimination of cytoskeletal actin filaments
would likely have an effect on the cytoskeletal reorgani-
sation for the MV release process (Fig. 7) but will need
further testing. Indeed, other proteins found to be
deiminated such as glyceraldehyde-3-phosphate dehydro-
genase also play likely roles in cytoskeleton organization
and assembly and warrant further investigation. While
the effects of PAD2/4 activity on the deimination of actin
and their inhibition by Cl-am have been largely measured
here on MV release, we certainly cannot exclude that
some of the vesicles measured were exosomes. Since the
process of multivesicular body recruitment to the plasma
membrane to release exosomal cargo likely involves actin
and microtubular elements of the cytoskeleton (76), it
may well be that PADs and deimination of actin are also
involved in exosomal release.
Several recent studies have reported the cytotoxic effect
of PAD inhibitors on cancer cells without affecting normal
cells (20,77,78). For instance, the potent PAD4 inhibitors
fluoramidine (F-am) and chloramidine (Cl-am) were
shown to exhibit cytotoxic effects at micromolar con-
centrations on several cancer cell lines including HL60,
MCF-7 and HT-29, whereas no effect was observed on
non-cancerous cells. Differentiation of HL60 and HT29
cells was also observed (70). Furthermore, a synergistic
effect has been shown whereby cell cytotoxicity was increa-
sed when combining PAD inhibitors with the cancer
drug doxorubicin (70). We now report a similar finding,
whereby PC3 prostate cancer cells treated with PAD-
inhibitor Cl-am and MTX exerted a synergistic cytotoxic
effect compared to MTX alone. We can now postulate a
novel mechanism for the synergistic effect of Cl-am/F-am
Fig. 7. The proposed role of PADs in microvesiculation and the potential therapeutic application of PAD inhibitors in anticancer
therapy. PAD2 and PAD4 are cytosolic enzymes, which during the course of cells being stimulated, through raised intracellular calcium
levels, to microvesiculate (e.g. using BzATP stimulation of P2X channels or NHS as a source of sublytic complement), translocate to the
nucleus (PAD2 and PAD4) or remain partially in the cytosol (PAD2). These PAD isozymes play a potential novel role in the biogenesis
of MV release. This may happen by influencing actin-cytoskeleton cleavage and actin rearrangement and/or by deimination of genes in
the nucleus through still unknown pathways involved in microvesicle biogenesis . The pharmacological inhibition of PADs with the pan-
PAD-inhibitor chloramidine (Cl-am) abrogates the release of MVs and when combined with the anticancer drug methotrexate (MTX)
works synergistically to induce increased cytotoxic effects and apoptosis of PC3 tumour cells.
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with doxorubicin, reported previously (70) and of Cl-am
with MTX as described here. Essentially, Cl-am, which
inhibits MV release through the inhibition of actin
deimination may thus sensitize the cancer cells to other
chemotherapeutic drug(s) (Fig. 7). Our present findings
are in accordance with our previous observations and
other studies (12) reporting that neoplastic cells are
rendered more sensitive to cancer drugs when their
microvesiculation processes are inhibited, as this may
prevent these cells from removing the drugs through MV
release [(12) and on-going studies at CMIRC].
Various studies have shown that MVs play a role in
cellular cross talk and act as carriers of active molecules
that have an effect at distal sites from the origin of MV
release. The presence of PAD4 has been reported in the
plasma of cancer patients, although how it reaches this
location remains unknown (46). It is thus tempting to
postulate that tumour cells may increase the production
of MVs through a PAD4-mediated mechanism, which
would also allow the PAD enzyme to be packaged in
the MVs and carried into the plasma where it could
deiminate various proteins such as antithrombin thus
aiding the spread of tumourigenesis indirectly.
In summary, our findings suggest that PAD isozymes 2
and 4 play a significant role in cellular microvesiculation.
This can happen either directly through the deimination
of cellular actins, which affects actin-cytoskeletal re-
arrangement, or indirectly through the deimination of
histone proteins in the nucleus. This is supported by the
observed changes in nuclear PAD translocation in con-
cert with PAD inhibition and changes in MV release, a
mechanism that still needs further detailed investigation.
Refined and isozyme-selective PAD inhibitors pose as
promising therapeutic agents for current therapy regimes
and may form part of novel future combination therapies
in various forms of cancers.
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